The Inflation Reduction Act (the “IRA”) requires drug manufacturers to pay rebates to Medicare when the prices of their Part B and Part D prescription drug increase faster than the rate of inflation. We recently discussed the guidance documents issued by the Centers for Medicare and Medicaid Services (“CMS”) detailing the proposed implementation of the Medicare Part B and Medicare Part D Prescription Drug Inflation Rebate Programs.
About
Sheela Ranganathan is an associate in the Corporate Practice Group in the firm's Washington, D.C. office and a member of the firm’s Healthcare Team.
Latest Post
More Posts
PBM Practices Receive Increased Federal Scrutiny
Tracking the Waivers: Implications of the Wind Down of the COVID-19 Public Health Emergency
CMS Releases Guidance on Implementation of Rebate Programs for Certain Medicare Part B and Part D Drugs
Private Equity and Digital Health in 2023: Policy Updates and Trends to Watch
CMS Issues CY2024 Proposed Rule for Medicare Advantage Organizations and Part D Sponsors
CMS Proposes to Amend Overpayment Rule, Remove Potential Overpayment and False Claims Act Liability for Mere Negligence
2023 Top-of-Mind Issues for Life Sciences Companies
CMS Issues CY2024 Proposed Rule for Medicare Advantage Organizations and Part D Sponsors
CMS Proposes to Amend Overpayment Rule, Remove Potential Overpayment and False Claims Act Liability for Mere Negligence
Private Equity & Healthcare: Antitrust Enforcement in 2023–PE Roll-Ups in the Cross Hairs
Private Equity & Healthcare: Antitrust Enforcement in 2023–PE Roll-Ups in the Cross Hairs
CMS Includes MAOs in Data Exchange and Prior Authorization Requirements
Pharmaceutical Manufacturers Ask EDVa to Allow Cost-Sharing Under the AKS
Pharmaceutical Manufacturers Ask EDVa to Allow Cost-Sharing Under the AKS
About
Sheela Ranganathan is an associate in the Corporate Practice Group in the firm's Washington, D.C. office and a member of the firm’s Healthcare Team.